A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

References

• Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. (2001) "Cancer statistics", CA Cancer J. Clin., 51(1), 15–36.
   Google Scholar
• Rai, KR., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. (1975) "Clinical staging of chronic lympho-cytic leukemia", Blood, 46(2), 219–234.
   PubMed Web of Science ®Google Scholar
• Rai, KR., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., et al. (2000) "Fludarabine compared with chloram-bucil as primary therapy for chronic lymphocytic leukemia", N. EngL J. Med., 343(24), 1750 — 1757.
   Web of Science ®Google Scholar
• Perkins, J.G., Flynn, J.M., Howard, R.S. and Byrd, J.C. (2002) "Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient popula-tion", Cancer, 94(7), 2033–2039.
   PubMed Web of Science ®Google Scholar
• Carter, P. (2001) "Improving the efficacy of antibody-based cancer therapies", Nat. Rev. Cancer, 1(2), 118 — 129.
   PubMed Web of Science ®Google Scholar
• Reff, M.E., Carner, K., Chambers, KS., Chinn, P.C., Leonard, J.E., Raab, R., et al. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood, 83(2), 435–445.
   PubMed Web of Science ®Google Scholar
• McLaughlin, P., Grillo-Lopez, A.J., Link, BK., Levy, R., Czucz-man, M.S., Williams, M.E., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lympho-ma: half of patients respond to a four-dose treatment program", J. Clin. Oncol., 16(8), 2825–2833.
   PubMed Web of Science ®Google Scholar
• Petryk, M. and Grossbard, M.L. (2000) "Rituximab therapy of B-een neoplasms", Clin. Lymphoma, 1(3), 186— 194; discussion 195 — 196.
   Google Scholar
• Nguyen, D.T., Amess, J.A., Doughty, H., Hendry, L. and Diamond, L.W. (1999) "IDEC-C2B8 anti-CD20 (rituximab) im-munotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients", Eur. J. Haematol., 62(2), 76–82.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., et al. (2001) "Rituximab dose-escalation trial in chronic lymphocytic leukemia", J. Clin. Oncol., 19(8), 2165 — 2170.
   Web of Science ®Google Scholar
• Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., et al. (2001) "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and accepta-ble toxicity", J. Clin. Oncol., 19(8), 2153–2164.
   Web of Science ®Google Scholar
• Thomas, D., O'Brien, S., Giles, F., Cortes, J., Faderl, S., Kantarjian, H., et al. (2001) "Single agent Rituxan is early stage chronic lymphocytic leukemia (CLL)", Blood, 98(11), 364a, abstract # 1533.
   Google Scholar
• Keating, M.J., Flinn, I., JaM, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002) "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study", Blood, 99(10), 3554–3561.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman, N., Osby, E., Lundin, J., Kadin, M., Osterborg, A. and Gruber, A. (2002) "Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia", Med. Oncol., 19(4), 277 — 280.
   Google Scholar
• Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., Porwit MacDonald, A., Repp, R., et al. (2003) "A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for pa-tients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas", Blood.
   Google Scholar
• Frampton, J.E. and Wagstaff, A.J. (2003) "Alemtuzumab", Drugs, 63(12), 1229–1243; discussion 1245-1246.
   PubMed Web of Science ®Google Scholar
• Ghobrial, I.M., Otteman, L.A. and White, W.L. (2003) "An EBV-positive lymphoproliferative disorder after therapy with alemtuzu-mab", N. Engl. J. Med., 349(26), 2570–2572; discussion 2570 — 2572.
   PubMed Web of Science ®Google Scholar
• Thai, C., Nguyen, D. and Dugan, K. (2001) "Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL)", Blood, 98, abstract # 366a.
   Google Scholar
• Nabhan, C. and Rosen, S.T. (2002) "Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia", Semin. °flea, 29(1 Suppl 2), 75–80.
   Google Scholar
• Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., et al. (2004) "Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia", Clin. Lymphoma, 4(4), 220–227.
   Web of Science ®Google Scholar
• Faderl, S., Thomas, D.A., O'Brien, S., Garcia-Manero, G., Kantarjian, H.M., Giles, F.J., et al. (2003) "Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies", Blood, 101(9), 3413–3415.
   PubMed Web of Science ®Google Scholar
• Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., et al. (2002) "Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, 100(3), 768–773.
   PubMed Web of Science ®Google Scholar